Evolus Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY Revenue (est.)
$330.5Mnext fiscal year
FY EPS (est.)
-$0.09next fiscal year
Monitoring Framework
Key Performance Indicators
Evolus Rewards Program Members Quarterly1.5M
Customer Reorder Rate Quarterly7,100.0%
Evolus Rewards Redemptions Quarterly255K
Watch Items
- U.S. FDA Approval of Evolysse SculptTrigger: Approval decision expected in late 2026Action: Monitor FDA regulatory announcements and company press releases for PMA approval status.
- European Commercial Scaling of Estyme HA GelsTrigger: Launch initiated on May 16, 2026Action: Track international revenue contribution and filler segment growth in upcoming quarterly reports.
Research as of 19 Jun 2026